NEW DRUGS ON THE HORIZON 2018 by Dan Dupuis
There are a number of new drugs in late stage trials that may soon become available to patients suffering from a wide array of either life threatening diseases or conditions that significantly affect a person’s quality of life. Read More…
4 DRUG AND BIOTECH STOCKS AWAITING FDA APPROVAL IN JULY 2018 by Kinjel Shah
We are into the second half of the year. It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. The regulatory body approved 17 novel drugs in the first half of 2018, which is less than the year-ago period figure of 23. However, with several FDA decision lined up for the second half, a higher number of drugs could be approved in the rest of the year. Read More…
Argentum Pharmaceuticals wins patent invalidation trial against the sole remaining patent protecting Janssen’s Zytiga.
The U.S. Patent & Trademark Office (PTO) issued a final written decision Wednesday in Argentum Pharmaceuticals LLC’s inter partes review (IPR) against the sole unexpired patent covering Janssen Oncology, Inc.’s Zytiga (abiraterone acetate). Janssen Oncology is a subsidiary of Johnson & Johnson. READ MORE…
THIS NEW, FDA-APPROVED SKIN CARE DRUG COULD HELP OVER 7.5 MILLION PEOPLE
Alleviating psoriasis symptoms has been a difficult feat to achieve for decades, but with new advances in the skin care industry, doctors are excited that a cure may be closer than ever before. While we still haven’t reached a final remedy yet, a new advancement in the treatment of psoriasis has people super excited. Bryhali Lotion 0.01% is a new topical treatment that uses an active ingredient called halobetasol to treat the condition. And as Allure reports, Bryhali Lotion has just been approved by the Food and Drug Administration, making doctors and patients alike excited to give the new medication a try. READ MORE…